Article Text

Download PDFPDF
Unravelling the risk of (intermediate) antitrypsin deficiency

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors were involved in reviewing the subject and planning the content and structure of the editorial. MQ was responsible for drafting the first and second versions with feedback and editing by AMT and RM. RM finalised the manuscript for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AMT has received research grants from CSL Behring (current) and Grifols (within the last 5 years) and consulting fees from CSL. RM has received consulting fees for educational activities and advisory boards between 2016 and 2020 sponsored by CSL Behring and Kamada.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles